Developing new technologies to create inhibitors for carbohydrate-binding proteins
Technologies for Directed Evolution of Glycoaptamers
This study is working on new tools to help find ways to block certain proteins that are important in diseases like cancer and autoimmune disorders, aiming to create special molecules that can target these proteins and improve treatment options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brandeis University NIH-funded |
| Lab location | 1 site (Waltham, United States) |
| Project ID | NIH-10907010 on NIH RePORTER |
What this research studies
This research focuses on creating innovative technologies to quickly discover inhibitors that target carbohydrate-binding proteins (CBPs). These proteins play a crucial role in various biological processes, including how cells communicate and how diseases like cancer and autoimmune disorders develop. The project aims to develop two types of glyco-F-RNA aptamers that can selectively bind to specific CBPs, enhancing their effectiveness in disrupting harmful interactions in the body. By using advanced techniques, the researchers hope to provide new tools for treating conditions linked to CBPs.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals suffering from conditions related to carbohydrate-binding protein interactions, such as atherosclerosis, diabetes, or certain cancers.
Not a fit: Patients with conditions unrelated to carbohydrate-binding proteins or those who do not have a significant immune or metabolic component may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for a range of diseases, including cancer, autoimmune disorders, and cardiovascular diseases.
How similar studies have performed: While the approach of developing glyco-F-RNA aptamers is innovative, similar strategies targeting carbohydrate interactions have shown promise in other research, indicating potential for success.
Where this research is happening
Waltham, United States
- Brandeis University — Waltham, United States (Active)
Researchers
- Principal investigator: Krauss, Isaac Jonathan — Brandeis University
- Study coordinator: Krauss, Isaac Jonathan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.